Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/41488

Title:	Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.
Authors:	Cohen, Stanley Genovese, Mark C Choy, Ernest Perez-Ruiz, Fernando Matsumoto, Alan Pavelka, Karel Pablos, Jose L Rizzo, Warren Hrycaj, Pawel Zhang, Nan Shergy, William Kaur, Primal View more
Keywords:	DMARDs (biologic) TNF-alpha anti-TNF inflammation rheumatoid arthritis View more
Mesh:	Adalimumab Adult Aged Aged, 80 and over Antibodies Antirheumatic Agents Arthritis, Rheumatoid Biosimilar Pharmaceuticals C-Reactive Protein Double-Blind Method Female Humans Male Middle Aged Severity of Illness Index Therapeutic Equivalency Young Adult View more
Issue Date:	Oct-2017
Citation:	Ann. Rheum. Dis..2017 Oct;(76)10:1679-1687
Abstract:	ABP 501 is a Food and Drug Administration-approved biosimilar to adalimumab; structural, functional and pharmacokinetic evaluations have shown that the two are highly similar. We report results from a phase III study comparing efficacy, safety and immunogenicity between ABP 501 and adalimumab.
PMID:	28584187
URI:	https://hdl.handle.net/20.500.12530/41488
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. 12 de Octubre > Artículos

Files in This Item:

File	Description	Size	Format
PMC5629940.pdf		1.62 MB	Adobe PDF	View/Open